Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 OUS Study)
- Conditions
- Pulmonary Hypertension
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Gradient Denervation Technologies
- Target Recruit Count
- 20
- Registration Number
- NCT06495970
- Locations
- 🇪🇸
Hospital Clínico Universitario de Valencia, Valencia, Spain
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
- Conditions
- Heart FailureGroup 2 Pulmonary Hypertension
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Gradient Denervation Technologies
- Target Recruit Count
- 30
- Registration Number
- NCT06052072
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension
- Conditions
- Heart Failure Patients With Pulmonary Hypertension
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Gradient Denervation Technologies
- Target Recruit Count
- 5
- Registration Number
- NCT05951166
- Locations
- 🇬🇪
Israeli-Georgian Medical Research Clinic Helsicore, Tbilisi, Georgia
🇬🇪Tbilisi Heart Clinic, Tbilisi, Georgia
News
Gradient's Pulmonary Artery Denervation System Receives FDA Breakthrough Designation for Pulmonary Hypertension
Gradient Denervation Technologies' novel ultrasound-based pulmonary denervation system has received FDA Breakthrough Device Designation, creating an expedited review pathway for this potentially life-changing technology.
Gradient Denervation Technologies Expands Pulmonary Hypertension Trial and Appoints Stanton Rowe to Board
Gradient Denervation Technologies appointed Stanton Rowe, a medical device entrepreneur, to its board of directors to leverage his expertise in medical technology development.